{
    "clinical_study": {
        "@rank": "161299", 
        "arm_group": [
            {
                "arm_group_label": "Niaspan", 
                "arm_group_type": "Experimental", 
                "description": "these are the first episode psychosis patients that are randomized to receive niaspan"
            }, 
            {
                "arm_group_label": "healthy control", 
                "arm_group_type": "No Intervention", 
                "description": "this is the group of healthy controls for cognitive outcome measures"
            }, 
            {
                "arm_group_label": "first episode control group", 
                "arm_group_type": "No Intervention", 
                "description": "first episode psychosis patients who are randomized to no intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to\n      antipsychotic medications will it help maintain or improve  cognitve functioning."
        }, 
        "brief_title": "Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis", 
        "condition": "Psychosis", 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        ALL SUBJECTS\n\n          1. Must understand the nature of the study, must provide written informed consent prior\n             to the conduct of any study procedures/assessments and are willing/able to\n             participate in study procedures/assessments as specified in this protocol.\n\n          2. Must be between the ages of 18 - 35\n\n        PATIENTS\n\n          1. Within one year of initial DSM 1V TR diagnosis of schizophreniform psychosis,\n             schizophrenia, schizoaffective disorder or psychotic disorder NOS\n\n          2. Outpatients\n\n          3. Females of child bearing potential who have a negative serum pregnancy test prior to\n             enrolment and agree to use a reliable method of birth control (use of oral\n             contraceptives or Norplant; contraceptive injections; contraceptive patch; double\n             barrier method; intrauterine devices; partner with vasectomy or abstinence) during\n             the study and for one month following the last dose of study drug.\n\n        HEALTHY CONTROLS\n\n        1. Age-matched to experimental groups\n\n        Exclusion Criteria:\n\n          1. Due to their underlying mental disorder are considered by the investigator(s) to be\n             unable to provide informed consent and/or unwilling or unable to participate in study\n             procedures/assessments\n\n          2. Are judged by the investigator(s) (based on history, mental status examination or\n             clinical impression) as being at significant risk of self-injurious/suicidal or\n             violent/homicidal behaviour\n\n          3. Meet criteria for substance abuse or dependence (excluding nicotine and caffeine) as\n             defined by DSM IV-TR at the time of screening and/or within the preceding 6 months\n\n          4. Have unstable medical, psychiatric, neurological or behavioural disorders that may\n             interfere in the conduct or interpretation of the study.\n\n          5. Have a history of pre-existing liver dysfunction and/or at screening have abnormal\n             liver function tests (ALT>2x upper limit of normal; AST>3x upper limit of normal;\n             Bilirubin>1.5x upper limit of normal)\n\n          6. Have a past or current history of  peptic ulcer, gout or bleeding problems\n\n          7. Have a past or current history of hypophosphatemia\n\n          8. Have a history of head injury resulting in loss of consciousness of > 5 minutes or\n             other neurological disorder (e.g., seizures, stroke, MS)\n\n          9. Are currently taking a vitamin or nutritional supplement containing a dose of\n             niacin/nicotinic acid above 100 mg/day.\n\n         10. Are currently receiving treatment with any of  the following medications:\n\n               1. Anticoagulants\n\n               2. Statins\n\n               3. Antihypertensives\n\n         11. Are currently receiving treatment for Type 1 or Type 2 diabetes\n\n         12. Have a history of allergic reactions to NIASPAN or any of its non-medicinal\n             ingredients (methylcellulose, povidone, stearic acid), niacin or nicotinic acid\n\n         13. Are currently participating in any other investigational drug study\n\n         14. Are a professional or staff member affiliated with the Nova Scotia Early Psychosis\n             Program or are an immediate family member defined as spouse, parent, child, sibling,\n             grandparent or grandchild"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01041053", 
            "nct_id": "NCT01720095", 
            "org_study_id": "CDHA_RS/2010-116"
        }, 
        "intervention": {
            "arm_group_label": "Niaspan", 
            "intervention_name": "Niaspan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Niacin", 
                "Nicotinic Acids", 
                "Antipsychotic Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 31, 2012", 
        "location": [
            {
                "contact": {
                    "last_name": "Heather I Milliken, MD", 
                    "phone": "902-473-2976"
                }, 
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H 2E2"
                    }, 
                    "name": "NS Early Psychosis Program"
                }, 
                "investigator": {
                    "last_name": "Heather I Milliken, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Heather I Milliken, MD", 
                    "phone": "902-473-2976"
                }, 
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H 2E2"
                    }, 
                    "name": "NS Early Psychosis Program"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (NIASPAN) as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis", 
        "overall_contact": {
            "last_name": "Heather I Milliken, MD", 
            "phone": "902-473-2976"
        }, 
        "overall_official": {
            "affiliation": "Capital District Health Authority, Canada", 
            "last_name": "Heather I Milliken, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Outcomes will be measured by comparison of pre-treatment, post-treatment and twelve month", 
            "measure": "standardized and experimental measures of attention, memory, and executive function. Measurement tools=MATRICS; DalCAB", 
            "safety_issue": "No", 
            "time_frame": "change in cognitive function from baseline to 3, 6, and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Capital District Health Authority, Canada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Capital District Health Authority, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}